Latest Breaking News On - Loren kalm - Page 3 : comparemela.com

[Ad hoc announcement pursuant to Art 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19

Group sales grew by 2%1 at constant exchange rates , driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there.

United statesMabthera rituxanGazyva gazyvaroSabine borngrRebekka schnellActemra roactemraBirgit masjostNathalie altermattEli lillyBruno eschliLoren kalmSileia urechActivase tnkaseThomas schineckerSimon goldsboroughKarsten kleine

F Hoffmann-La Roche Ltd: Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19

F Hoffmann-La Roche Ltd: Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesDennis riedlBirgit masjostSimon goldsboroughGazyva gazyvaroActivase tnkaseEli lillyKirti pandeyActemra roactemraMabthera rituxanThomas schineckerSabine borngrNathalie altermattSileia urechLoren kalmKarsten kleine

F Hoffmann-La Roche Ltd: FDA approves Roche s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

F Hoffmann-La Roche Ltd: FDA approves Roche s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesLoren kalmSabine borngrDennis riedlBruno eschliNathalie altermattRebekka schnellBirgit masjostSimon goldsboroughKirti pandeySileia urechLevi garrawayKarsten kleineKen culverHead of global product developmentKamakura research laboratories

FDA approves Roche s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung.

United statesLevi garrawayRebekka schnellKarsten kleineSimon goldsboroughSileia urechNathalie altermattBruno eschliKirti pandeyKen culverLoren kalmSabine borngrBirgit masjostFrench cooperative thoracic intergroupClinical affairsAmerican cancer society

Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer s disease diagnosis

The Elecsys® pTau217 plasma biomarker test is being developed as part of an ongoing partnership between Roche and Eli Lilly and CompanyOnce approved, the test will aid healthcare providers in.

United statesSimon goldsboroughKirti pandeyLoren kalmSileia urechEli lillyBruno eschliKarsten kleineMatt sauseBirgit masjostNathalie altermattSabine borngrAnne whiteRebekka schnellBreakthrough devices programDrug administration